|
PARASYMPATHOMIMETICS MAY COUNTERACT EACH OTHER EFFECTS
|
CO-ADMINISTRATION MAY LEAD TO INCREASED PARASYMPHATHOMIMETIC EFFECT CAUSING BRADYCARDIA, HYPOTENSION, A-V CONDUCTION ABNORMALITIES, FLUSHING, DIARRHOEA, ABDOMINAL PAIN, INCREASED SALIVATION ETC
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ECHOTHIOPATE IODIDE POTENTIATES THE EFFECT OF OTHER CHOLINESTERASE INHIBITORS CAUSING INCREASED CHOLINERGIC SIDE EFFECTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|